Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
'More like a partnership': A qualitative evaluation of Communication Coaching for Sonographers (CCS) in obstetric ultrasound.
Kaur E, Arezina J, Bryant L, Pollak K, Wallace R, Harrison G, Bender Atik R, Sicklen R, Coates J, Hardicre N, Lardner T, Horwood K, Beety H, Arnold J, Johnson J. Kaur E, et al. Among authors: horwood k. Ultrasound. 2024 Sep 25:1742271X241277127. doi: 10.1177/1742271X241277127. Online ahead of print. Ultrasound. 2024. PMID: 39555154 Free PMC article.
Communication coaching for sonographers (CCS): Preliminary evaluation of a novel intervention to improve unexpected news delivery.
Johnson J, Kaur E, Arezina J, Bryant LD, Wallace R, Harrison G, Bender Atik R, Coates J, Hardicre N, Sicklen R, Lardner T, Horwood K, Beety H, Arnold J, Pollak KI. Johnson J, et al. Among authors: horwood k. PEC Innov. 2023 Oct 31;3:100231. doi: 10.1016/j.pecinn.2023.100231. eCollection 2023 Dec 15. PEC Innov. 2023. PMID: 38076485 Free PMC article.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Betsch R, Xu L, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, McNeish I, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Mol Cancer. 2024 Aug 5;23(1):158. doi: 10.1186/s12943-024-02048-1. Mol Cancer. 2024. PMID: 39103848 Free PMC article.
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. O'Connell CL, et al. Among authors: horwood k. Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810. Clin Cancer Res. 2022. PMID: 36222848 Free PMC article. Clinical Trial.
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, Xing Z, Allan P, Bowtell DDL, Mes-Masson AM, Provencher DM, Rahimi K, Kelemen LE, Fasching PA, Doherty JA, Goodman MT, Goode EL, Deen S, Pharoah PDP, Brenton JD, Sieh W, Mateoiu C, Sundfeldt K, Cook LS, Le ND, Anglesio MS, Gilks CB, Huntsman DG, Kennedy CJ, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Kaufmann S, Churchman M, Gourley C, Stephens AN, Meagher NS, Ramus SJ, Antill YC, Campbell I, Scott CL, Köbel M, Gorringe KL; GAMuT Collaborators. Kang EY, et al. Mod Pathol. 2021 Jan;34(1):194-206. doi: 10.1038/s41379-020-0618-9. Epub 2020 Jul 28. Mod Pathol. 2021. PMID: 32724153 Free PMC article.
51 results